Investing.com - Sage Therapeutic (NASDAQ: SAGE) reported fourth quarter EPS of $-2.47, $0.10 worse than the analyst estimate of $-2.37. Revenue for the quarter came in at $2.87M versus the consensus estimate of $1.95M.
Sage Therapeutic's stock price closed at $45.11. It is up 25.41% in the last 3 months and up 34.34% in the last 12 months.
Sage Therapeutic saw 4 positive EPS revisions and 12 negative EPS revisions in the last 90 days. See Sage Therapeutic's stock price’s past reactions to earnings here.
According to InvestingPro, Sage Therapeutic's Financial Health score is "fair performance".
Check out Sage Therapeutic's recent earnings performance, and Sage Therapeutic's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar